{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-261661","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2026-06-08T20:01:29+00:00","discovered_at":"2026-06-08T20:03:00.645529+00:00","generated_at":"2026-06-08T20:07:20.649636+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RemeGen gets NMPA nods for telitacicept in IgAN and Sjögren’s; Vor Bio holds ex-China rights","bullets":["First BAFF/APRIL-targeting therapy approved for IgA nephropathy; conditional NMPA approval based on Phase 3 TELIGAN trial showing 55% placebo-adjusted UPCR reduction.","First regulatory approval ever for Sjögren’s disease in China; Phase 3 met primary and secondary endpoints (ESSDAI, ESSPRI).","Telitacicept now has five approved indications in China; Vor Bio holds exclusive development/commercialization rights outside Greater China.","Phase 3 IgAN results recently published in NEJM; eGFR stable at 39 weeks vs declines on placebo.","Vor Bio CEO cites milestone validating dual BAFF/APRIL inhibition as potential foundational therapy for autoimmune diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-261661","json":"https://secwatch.observer/filing/0001193125-26-261661.json","markdown":"https://secwatch.observer/filing/0001193125-26-261661.md","text":"https://secwatch.observer/filing/0001193125-26-261661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526261661/0001193125-26-261661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526261661/vor-20260608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T20:07:20.649636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}